美沙拉嗪联合培菲康治疗溃疡性结肠炎患者的疗效及对 TLR4、MyD88的影响  

Effects of mesalazine combined with bifico on the treatment of ulcerative colitis and on TLR4 and MyD88

作　　者：张永萍[1] 周益峰[2] 汪平凡[1] 高虎云[1] 俞锡灿[1] 

机构地区：[1]新昌县人民医院消化内科,浙江省新昌312500 [2]上海长海医院消化内科

出　　处：《中国医师杂志》2014年第4期498-500,共3页Journal of Chinese Physician

摘　　要：目的：观察美沙拉嗪联合培菲康治疗溃疡性结肠炎（UC）的疗效及对患者血清Toll样受体4（TLR4）、髓样分化因子88（MyD88）的影响。方法将86例UC患者按随机数字表法分为观察组和对照组，每组43例；观察组给予美沙拉嗪联合培菲康治疗，对照组单纯给予美沙拉嗪治疗，8周为一疗程；观察两组患者的临床疗效，测定血清中TLR4、MyD88的含量变化，并记录治疗中的不良反应情况。结果观察组临床总有效率（95.35％）明显高于对照组（81.40％），差异有统计学意义（ P ＜0.05）；两组患者血清TLR4、MyD88含量均较治疗前明显下降（ P ＜0.05或P ＜0.01），且观察组TLR4的下降比对照组更为明显（ P ＜0.05）；两组不良反应发生率比较差异无统计学意义（ P ＞0.05）。结论美沙拉嗪联合培菲康治疗UC疗效确切、安全性好，其作用可能与调节外周血TLR4、MyD88的含量有关。Objective To investigate the clinical efficacy of mesalazine combined with bifico in the treatment of ulcerative co -litis （UC） and its effect on toll-like receptor 4 （TLR4） and myeloid differentiation factor 88 （MyD88）.Methods A total of 86 cases of UC was randomly divided into the observation and control groups with 43 cases in each group .The observation group was given me-salazine combined bifico treatment , and the control group was given mesalazine , and eight weeks as a course of treatment .The clinical efficacy was observed .Serum TLR4 and MyD88 were tested.Adverse reaction in treatment was recorded .Results The total effective rate （95.35%） in observation group was significantly higher than that （81.40%） in control group（ P ＆lt;0.05）.The serum TLR4 and MyD88 after treatment of two groups were significantly lower than that before treatment , respectively （ P ＆lt;0.05 or P ＆lt;0.01 ） , and the decline in TLR4 of observation group was superior to that of control group （ P ＆lt;0.05 ） .The difference of adverse reaction rate in two groups was not significant （ P ＆gt;0.05 ） .Conclusions Mesalazine combined with bifico in the treatment of UC is safe and effective . The effect may be related to regulation of peripheral blood TLR 4 and MyD88 content .

关 键 词：结肠炎 溃疡性 药物疗法 氨水杨酸 治疗应用 有益菌种 治疗应用 Toll样受体4 血液 髓样分化因子88 血液 

分 类 号：R574.62[医药卫生—消化系统]